Correction to: Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsRenal Diseases and Glomerulopathies · Lymphatic Disorders and Treatments · Chronic Lymphocytic Leukemia Research
This is a correction to: Safak Mirioglu, Lisa Daniel-Fischer, Ilay Berke, Syed Hasan Ahmad, Ingeborg M Bajema, Annette Bruchfeld, Gema M Fernandez-Juarez, Jürgen Floege, Eleni Frangou, Dimitrios Goumenos, Megan Griffith, Sarah M Moran, Cees van Kooten, Stefanie Steiger, Kate I Stevens, Kultigin Turkmen, Lisa C Willcocks, Andreas Kronbichler, Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group, Nephrology Dialysis Transplantation, Volume 39, Issue 4, April 2024, Pages 569–580, https://doi.org/10.1093/ndt/gfae025
In the supplementary material, the phrase:
‘Gonadal toxicity in women was shown in patients exposed to a cumulative dose of greater than 5 grams [17].’
Has been corrected to read:
‘A paucity of data exists related to secondary amenorrhea following cyclophosphamide exposure in podocytopathies. In SLE, exposure to ≥8 g/m2 of cyclophosphamide in patients ≥32 years predicted sustained amenorrhea. Even at 5 g/m2, the estimated risk was 32% (PMID: 12 375 322). In women with AAV (mean age of 35), diminished ovarian reserve was reported in 75% of participants who received oral cyclophosphamide (PMID: 22127969).’